An animal model of wound botulism was developed in mice using an inoculum of Clostridium botulinum type A spores. The number of C. botulinum in infected wounds was quantitated by culturing on egg yolk agar, and the level of C. botulinum toxin in infected wound tissue was measured by a bioassay in mice and by an enzyme-linked immunosorbent assay. All infected mice receiving no further treatment developed neuroparalytic symptoms consistent with botulism after an incubation period of ca. 48 h, and all of these animals died. Serotherapy with C. botulinum type A antitoxin initiated 24 h postchallenge reduced the mortality rate to 5%. Treatment with metronidazole 2 to 24 h postchallenge resulted in recovery rates of 40 to 91%.
Wound botulism results from the in vivo production of Clostridium botulinum toxin after colonization of injured tissue with C. botulinum. Although the pathogenicity of C. botulinum in experimental wound infections was studied as early as 1920 (8) , little information is available regarding the pathophysiology of the disease and the availability of effective therapeutic measures. In an attempt to gather further information about wound botulism, we studied the growth and toxigenicity of a C. botulinum type A strain in an animal model of wound infection and compared the results with in vitro studies. We also investigated the effects of serotherapy and metronidazole therapy on the outcome of the disease in mice.
A total of 145 adult CD-1 mice (Charles River Breeding Laboratories, Inc., Wilmington, Mass.) received a 0.25-ml subcutaneous inoculation of autoclaved rat cecal contents (11) and 2 x 102 detoxified spores (spores heated at 80°C for 15 min) of C. botulinum type A, strain A28. The autoclaved rat cecal contents were prepared by diluting the cecal contents of rats with PYG broth (Scott Laboratories, Inc., Fiskeville, R.I.) (cecal content-PYG ratio, 1:3) as described previously (11) . The resultant slurry was filtered through coarse surgical gauze and autoclaved at 121°C for 60 min. For kinetic studies, mice were sacrified at various times postchallenge. At each time period the wound from each of two mice was incised, and the exudate was collected aseptically, placed in a small vial, and kept frozen at -706C until used. Before being tested, the frozen exudate was thawed and homogenized in sterile distilled water containing 1.5% dithiothreitol (11) . Quantitation of C. botulinum was performed with 10-fold dilutions of duplicate samples of the wound homogenate plated on egg yolk agar medium (6) , and toxin levels were determined by a mouse bioassay (MBA) (7) and by an enzyme-linked immunosorbent assay (ELISA) an previously described (3, 4). By using an aseptic technique, we demonstrated no microorganism except C. botulinum in the infected wounds.
To study the in vitro growth kinetics of and toxin production by the organism, we inoculated tubes containing 0. botulinum type A antitoxin prepared in rabbits (3) was administered intraperitoneally to 30 mice in a single dose of 0.2 or 0.5 ml (equivalent to 1.2 or 3 IU) at 24 h postchallenge. Twenty-eight untreated mice with wounds infected with C. botulinum served as controls.
In vivo replication of the bacteria in the wound was measured from 9 to 60 h ( Table 1) . The peak bacterial concentration of 3 x 108/ml of exudate was noted at 36 h postchallenge, coinciding with the appearance of a purulent discharge. Although considerable amounts of toxin were detected by ELISA and MBA as early as 24 h postchallenge (Table 1) , the first sign of disease was not observed until 24 h later. In two mice, the 48 h-incubation period was extended to ca. 56 h. Signs and symptoms of botulism lasted between 2 and 4 h, followed by death in all untreated controls. Signs of disease included labored abdominal breathing, constriction of the abdomen, limb paresis, and total paralysis. (14) . In 1929, Coleman (2) reported that ca. 25 spores would produce a fatal wound infection in guinea pigs. The clinical relevance of these observations became apparent with the recognition of botulism as a complication of wounds (10, 12) . Wound botulism is rare, but it is also a serious disease that is likely to go unrecognized and is poorly understood.
In the present study we were able to produce botulism in mice with as few as 10 spores of C. botulinum type A, strain A28. Inoculum size did not influence the clinical manifestations or the length of the incubation period. Thus, mice to 100,000 spores (data not shown). Although the peak bacterial levels in the wound exudate and the broth culture were very close, the highest concentration of C. botulinum toxin produced in vivo was 10-fold lower than that observed in vitro (Tables 1 and 2 ). (It should be noted that optical density readings for the ELISA appear similar because the broth cultures were tested at a 10-fold-greater dilution.)
Recommendations for the treatment of wound botulism include local debridement, antibiotics, and antitoxin (10, 12) . These guidelines are somewhat restrained by the paucity of clinical cases and the lack of experimental animal work to document efficacy. As respiratory insufficiency is the most serious result of infection, intensive ventilatory support is highly recommended. Our limited studies dealing with the treatment of experimentally infected animals showed that antitoxin administration was more effective than metronidazole administration when the treatment was initiated 24 h postchallenge. Once the symptoms of botulism appeared in mice, neither treatment was helpful. Metronidazole was selected for this study because of its unique bactericidal activity against anaerobic bacteria (13) , because of in vitro studies showing that C. botulinum is highly sensitive to metronidazole (5, 15) , and because of a previous study showing the unique efficacy of metronidazole as compared with alternative drugs for the delayed treatment of infections involving Bacteroidesfragilis (1). The utility of antimicrobial agents in treating patients with wound botulism is unclear (10, 12) .
The laboratory procedures commonly used to establish a diagnosis of wound botulism include culturing of wound tissue or exudate for C. botulinum and bioassaying of serum samples for C. botulinum toxin (12) . However, the organism may simply colonize wounds without causing disease, so that laboratory isolation cannot be considered diagnostic (9) . Further, circulating toxin has been detected in less than 50% of reported cases of wound botulism (10, 12) . Our results suggest that an analysis of wound exudate for C. botulinum toxin may facilitate laboratory study and may also permit an earlier diagnosis at a time when therapy would appear to be more effective. To our knowledge this is the first time C. botulinum toxin has been shown in infected wound tissue. The longer incubation period (4 to 14 days [12] ) of wound botulism in humans may be advantageous for the early diagnosis and treatment of the disease. Even after the appearance of symptoms, an assay of an infected wound for C. botulinum toxin may prove to be a reliable diagnostic procedure for laboratory confirmation of wound botulism. 
